Provided by Tiger Fintech (Singapore) Pte. Ltd.

Beam Therapeutics, Inc.

15.27
-1.1900-7.23%
Post-market: 15.600.3299+2.16%19:59 EDT
Volume:5.49M
Turnover:83.79M
Market Cap:1.52B
PE:-3.33
High:16.67
Open:15.83
Low:14.72
Close:16.46
Loading ...

Cathie Wood’s ARK Investment buys 143K shares of Beam Therapeutics today

TIPRANKS
·
1 hour ago

Cathie Wood Just Made A Bold Move—Why She Spent Over $65M On Tesla, Robinhood, And Coinbase 'As The Market Crashed'

Benzinga
·
6 hours ago

When Emergencies Strike Local Broadband Providers Deliver a Communications Lifeline for Their Communities With Calix SmartTown

Business Wire
·
Yesterday

Is Beam Therapeutics Inc. (BEAM) the Best Gene-Editing Stock to Buy?

Insider Monkey
·
02 Apr

Biotech stocks slide as Marks resignation seen being negative for sector

TipRanks
·
01 Apr

Shares of Gene Therapy Makers and Developers Fall After Report That FDA Official Peter Marks Has Resigned

THOMSON REUTERS
·
31 Mar

Solid Biosciences Down 10.5%, Taysha Gene Therapies Down 14%

THOMSON REUTERS
·
31 Mar

BUZZ-Gene therapy makers slide on reports that FDA official Peter Marks resigns

Reuters
·
31 Mar

BUZZ-U.S. STOCKS ON THE MOVE-GameStop, Oxford Industries, Wolfspeed

Reuters
·
29 Mar

Promising Genomics & Synthetic Biology Stocks to Consider in 2025

Zacks
·
28 Mar

BEAM's IND for BEAM-302 in Genetic Disorder Study Gets FDA Clearance

Zacks
·
28 Mar

BUZZ-Beam Therapeutics rises after FDA clears genetic disorder drug application

Reuters
·
28 Mar

Top Calls on Wall Street: Netflix, Tesla, Nike, Meta, Disney, Lululemon & More

Tiger Newspress
·
28 Mar

BofA Securities Upgrades Beam Therapeutics to Buy From Neutral

MT Newswires Live
·
28 Mar

Beam Therapeutics Inc : Bofa Global Research Raises to Buy From Neutral

THOMSON REUTERS
·
28 Mar

Beam Therapeutics New Drug Application for Alpha-1 Antitrypsin Deficiency Gets FDA Clearance

MT Newswires Live
·
28 Mar

Beam announces FDA clearance of BEAM-302 investigational new drug application

TIPRANKS
·
28 Mar

BRIEF-Beam Therapeutics Announces Clearance Of Investigational New Drug Application For BEAM-302 For The Treatment Of Alpha-1 Antitrypsin Deficiency (AATD) By The United States (U.S.) Food And Drug Administration

Reuters
·
28 Mar

Beam Therapeutics Announces Clearance of Investigational New Drug Application for Beam-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (Aatd) by the United States (U.S.) Food and Drug Administration

THOMSON REUTERS
·
28 Mar

Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration

GlobeNewswire
·
28 Mar